[The elder patient with advanced liver disease].
The increasing number of elder patients with advanced liver diseases requires a special medical competence in this field. The process of aging influences pharmacokinetic and pharmacodynamic properties. Medical measures in elder patients have to submit in particular a careful utility/risk-analysis. The most severe liver disease is the decompensated cirrhosis with its complications. Medical treatment of common cirrhotic complications is not age-dependent. Also the antiviral-therapy with nucleosid analoga in chronic hepatitis B, with or without cirrhosis, can be applied in elder patients without restrictions. However in elder patients with chronic hepatitis C the indication for antiviral treatment is restricted only to a limited number of patients. Important aspects justifying the therapy with PEG-Interferon plus Ribavirin also in elder patients are disease progression, a good clinical condition as well as the motivation of the patient. The established concepts for treatment of autoimmune hepatitis and primary biliary cirrhosis are applicable to elder patients in the same way. The hepatocellular carcinoma is a complication of liver cirrhosis and a frequent malignant tumor in this group of patients. For therapy of hepatocellular carcinoma surgical and interventional procedures are available, partially with a curative account. The systemic medical treatment is disappointing until now. The liver transplantation is generally not a realistic option for aged patients.
Hopf
U
U
Universitätsmedizin Berlin, Charité, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin. sonja.niederhausen@charite.de
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D004359:Drug Therapy, Combination; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D019693:Hepatitis, Autoimmune / Q000188:drug therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000628:therapy; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy; D008107:Liver Diseases / Q000188:drug therapy / Q000628:therapy*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D015201:Meta-Analysis as Topic; D011379:Prognosis
D000998:Antiviral Agents